BUZZ-GS ups Morphosys to 'neutral' ahead of MANIFEST-2 trial readout

** Goldman Sachs upgrades Morphosys MORG.DE to "" from "sell" ahead of the "significant" readout of the German drugmaker's MANIFEST-2 trial of BET inhibitor pelabresib

** Shares in Morphosys are up 8%, topping Germany's small-cap index .SDAXI, set for a best day since May, when it closed 8.9 % higher

** The brokerage says that pelabresib has a potentially "best-in-class" profile among emerging myelofibrosis (MF) therapies

** The broker sees MF as an area of growing industry and investor interest, as the active development program with modalities might enter the market in the foreseeable future, impacting many global healthcare companies

** Other stocks with exposure to the theme include Incyte Corp INCY.O, AbbVie ABBV.N, Bristol-Myers Squibb BMY.N, Geron GERN.O, GSK GSK.L, Merck & Co MRK.N and Swedish Orphan Biovitrum SOBIV.ST

** Out of 13 analysts that cover Morphosys, seven rate the stock "buy,"​ three rate it "hold" and three rate the stock "strong sell"/"sell" - LSEG data

(Reporting by Mateusz Dobrzyniewski)

((Mateusz.dobrzyniewski@thomsonreuters.com))